甲基丁香酚对变应性鼻炎大鼠鼻黏膜水通道蛋白5的影响
Effect of methyl eugenol on nasal mucosal aquaporin 5 in rats with allergic rhinitis

目的 观察甲基丁香酚对变应性鼻炎大鼠鼻黏膜水通道蛋白(aquaporin,AQP)5表达的影响,并探讨其意义。方法 Wistar 大鼠126只随机分为正常对照组,变应性鼻炎(allergic rhinitis,AR)模型对照组,布地奈德阳性对照组,甲基丁香酚80 mg/kg组、40 mg/kg组、20 mg/kg组及10 mg/kg组,每组18只,除正常对照组外,其余组大鼠经卵清蛋白(ovalbumin,OVA)致敏建立变应性鼻炎模型,造模成功后分别给予蓖麻油、布地奈德及对应剂量甲基丁香酚干预,于给药1、2、4周后应用免疫组织化学方法观察鼻黏膜AQP5的分布,Western blotting比较各组鼻黏膜中AQP5的表达,Real-time PCR比较AQP5 mRNA的表达。结果 AQP5主要位于鼻黏膜腺上皮及导管上皮细胞的胞膜和胞质。AR模型对照组大鼠鼻黏膜的AQP5及AQP5 mRNA均较正常对照组表达减少(P<0.05)。各给药组大鼠鼻黏膜AQP5及AQP5 mRNA均较AR模型对照组有不同程度增高。药物干预1、2、4周,布地奈德阳性对照组AQP5的表达与正常对照组比较,差异均无统计学意义(P均>0.05), 与AR模型对照组比较,差异均有统计学意义(P均<0.05);布地奈德阳性对照组的AQP5 mRNA分别与正常对照组及AR模型对照组比较,差异均有统计学意义(P均<0.05)。干预2周后,甲基丁香酚各剂量组AQP5的表达即与布地奈德阳性对照组比较,差异无统计学意义(P>0.05)。干预1周, 20 mg/kg组的AQP5 mRNA与正常对照组比较,差异无统计学意义(P>0.05);与模型对照组比较,差异有统计学意义(P<0.05)。结论 甲基丁香酚可能通过上调AQP5的表达减轻鼻黏膜腺体水肿程度、减少腺体分泌,从而缓解变应性鼻炎鼻痒、喷嚏及流涕等症状。
Objective: To observe the effect of methyl eugenol on the expression of aquaporin (AQP) 5 in nasal mucosa of rats with allergic rhinitis and to explore its significance.Methods: In the study, 128 Wistar rats were randomly divided into normal control group, AR model control group, budesonide positive control group, 80 mg/kg group, 40 mg/kg group, 20 mg/kg group and 10 mg/kg group, and ovalbumin (OVA) was used to establish the model of allergic rhinitis. After successful modeling, castor oil, budesonide and corresponding doses of methyl eugenol were given respectively. After 1, 2 and 4 weeks of administration, the distribution of AQP5 in nasal mucosa was observed by immunohistochemistry. The expression of AQP5 in nasal mucosa of each group was compared by Western blotting. The expression of AQP5 mRNA was compared with real-time PCR.Results: AQP5 was mainly located in the glandular epithelium and ductal epithelial cell membrane and cytoplasm. The expression of AQP5 and AQP5 mRNA in nasal mucosa of the rats in the model control group was lower than that in the normal control group (P<0.05). AQP5 and AQP5 mRNA in nasal mucosa of the rats in each treatment group were higher than those in the model control group in varying degrees. The expression of AQP5 in the budesonide group was not significantly different from that in the normal control group 1, 2 and 4 weeks after drug intervention(P>0.05), but there was significant difference between the budesonide group and the model control group (P<0.05). The expression of AQP5 mRNA in the budesonide group was significantly different from that in the normal control group and the model control group (P<0.05).After 2 weeks of intervention, the expression of AQP5 in each dose group of methyleugenol was not significantly different from